Tarsus Pharmaceuticals Inc Stock News

TARS has passed the milestone of $100M in sales per quarter with Xdemvy. TARS guides for softer Q3'25 growth due to seasonality, but expects direct-to-consumer campaigns and reimbursement to drive stronger growth in Q4'25 and beyond. TARS pipeline includes international Xdemvy launches and a new ocular rosacea trial, offering significant future revenue potential beyond current indications.

IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability and a slump that can lead to the firm's eventual demise.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Aziz Mottiwala - Chief Commercial Officer Bobak R. Azamian - Co-Founder, President, CEO & Chairman David Nakasone - Head of Investor Relations Jeffrey S.

Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY ® launch, an increase of 152% year over year

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its second quarter 2025 financial results and provide a corporate update.

IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

TARS has been marketing Xdemvy (lotilaner) aggressively, with Q1'25 seeing advertisement on network TV, moving beyond previous advertising on streaming platforms. TARS can expand lotilaner beyond Demodex blepharitis, with trials set to initiate in H2'25 in ocular rosacea and 2026 for Lyme disease prevention. TARS is guiding for up to a 25% increase in bottles of Xdemvy dispensed in Q2'25, compa...